Inhibikase (IKT) Officer Discloses 1.01M Shares After CorHepta Acquisition

Rhea-AI Filing Summary

Cabell Christopher filed an amended Form 3 to report ownership of 1,014,846 shares of Inhibikase Therapeutics, Inc. (IKT) common stock received as merger consideration from the acquisition of CorHepta Pharmaceuticals, Inc. Closed on 02/21/2025. Of the shares, 169,141 vested at closing, 507,423 vest on the first anniversary of closing, and the remaining 338,282 are subject to a milestone vesting schedule: 25% vests upon achievement of a specified milestone and 75% vests on the first anniversary of closing, with forfeiture of the 338,282 shares if the milestone is not achieved by that anniversary. The reporting person is identified as a director and an officer (President & Head of R&D). The amendment states these shares were inadvertently omitted from the original Form 3 filed on 02/25/2025.

Positive

• Disclosure corrected via Form 3/A to include previously omitted shares, improving regulatory compliance
• Vesting structure ties a substantial portion of equity to continued service and achievement of a milestone, aligning incentives

Negative

• Potential dilution for existing shareholders from issuance of 1,014,846 shares (magnitude not specified)
• Contingent forfeiture means certain shares will be lost if the milestone is not achieved by the first anniversary, indicating performance risk

Insights

Financial Analyst

TL;DR: Officer received ~1.01M acquisition shares with time- and milestone-based vesting; confirms compensation tied to integration and clinical milestones.

The filing documents issuance of 1,014,846 common shares to an executive following the CorHepta acquisition closed 02/21/2025. The disclosed vesting schedule splits immediate, time-based, and milestone-contingent tranches, which aligns the recipient's economic interest with achievement and continued service. This is a common post-merger equity treatment for key personnel and can affect share count and governance over time. The amendment corrects an earlier omission, improving disclosure completeness.

Corporate Governance Expert

TL;DR: Amendment improves Section 16 transparency; vesting terms introduce performance conditions tied to retention and milestone achievement.

The Form 3/A remedies an omission and clarifies beneficial ownership for a director/officer, addressing Section 16 reporting obligations. The combination of immediate vesting, anniversary-based vesting, and milestone-contingent vesting is designed to retain the executive and link compensation to specified achievements. The forfeiture clause for the contingent tranche creates a clear performance contingency that should be tracked for future disclosures.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cabell Christopher

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/21/2025

3. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Head of R&D

5. If Amendment, Date of Original Filed (Month/Day/Year)
02/25/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,014,846(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 3 amendment is being filed solely to include shares of common stock which were inadvertently omitted from the original Form 3 filed by the Reporting Person on February 25, 2025.

2. Represents shares of common stock issued to the Reporting Person as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. ("CorHepta") on February 21, 2025 (the "Closing Date") by the Issuer, pursuant to the Agreement and Plan of Merger and Reorganization by and among the Issuer, Project IKT Merger Sub, Inc., CorHepta, and Preston S. Klassen, solely in his capacity as sellers' representative. Of these, 169,141 shares vested on the Closing Date, 507,423 shares shall vest on the first anniversary of the Closing Date. 25% of the remaining 338,282 shares will vest upon achievement of a certain milestone and 75% will vest on the first anniversary of the Closing Date, subject to the Reporting Person's continued service through such date; provided that, if the milestone is not achieved by the first anniversary of the Closing Date, all 338,282 shares shall be forfeited.

	/s/ Mark Iwicki, attorney-in-fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What shares did Cabell Christopher report in the Form 3/A for IKT?

The amendment reports 1,014,846 shares of Inhibikase Therapeutics common stock received as merger consideration from CorHepta.

When was the transaction that generated the reported shares?

The acquisition closed on 02/21/2025, which is the Date of Event requiring the Form 3 filing.

What is the vesting schedule for the reported 1,014,846 shares?

169,141 shares vested at closing; 507,423 vest on the first anniversary of closing; 338,282 are contingent: 25% vests upon a milestone and 75% vests on the first anniversary, with forfeiture if the milestone is not achieved by that anniversary.

What is Cabell Christopher's role at Inhibikase?

The filing lists the reporting person as a Director and an Officer with the title President & Head of R&D.

Why was this Form 3 amended?

The amendment states the shares were inadvertently omitted from the original Form 3 filed on 02/25/2025, so this filing adds those omitted shares.

When was the amended Form 3 signed and submitted?

The signature block shows the form was signed by an attorney-in-fact, Mark Iwicki, on 08/28/2025.